2-agonist salbutamol/albuterol was available for rescue use throughout the study.

2 trials

Sponsors

NOVARTIS BIOSCIENSES PERU S.A.,

Unknown Phase

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease INTRUST1

Active, not recruitingPER-049-09

NOVARTIS BIOSCIENSES PERU S.A.,

Target: 42Updated: 2023-09-04

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) GLOW2

Active, not recruitingPER-095-09

NOVARTIS BIOSCIENSES PERU S.A.,

Target: 20Updated: 2023-09-04